Misoprostol is a cytoprotective prostaglandin E₁ analog, which displays agonist activity against the EP₁, EP₂, EP₃ and EP₄ subtypes of the prostaglandin E receptor stably expressed in Chinese hamster ovary cells, with Ki values of 120, 250, 67 and 67 nM. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, thus exerting protective effect on the gastrointestinal mucosa. Misoprostol has been approved for the prevention and treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in patients taking NSAIDs and at high risk for ulceration.

References:

1. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. British Journal of Pharmacology, 1997, 122(2): 217-224.

2. Krugh M, Maani CV. Misoprostol. 2021 Jul 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.

3. Izzettin FV, Sancar M, Okuyan B, et al. Comparison of the protective effects of various antiulcer agents alone or in combination on indomethacin-induced gastric ulcers in rats. Experimental and Toxicologic Pathology, 2012, 64(4): 339-343.